Biota Announces Relenza Royalty for March 2011 quarter

MELBOURNE, Australia--(BUSINESS WIRE)-- Biota Holdings Limited (ASX:BTA) advises that it has received written notification from GlaxoSmithKline that Relenza sales were $14.1 million and indicative royalties were $1.0 million, for the three months ended 31 March 2011. The figures were calculated on an Australian dollar exchange rate of 1.5576 to the UK pound, although the actual payment will be calculated on exchange rates at 30 April 2011.

Indicative Relenza royalty income for the nine months to 31 March 2011 is $4.3 million.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir®, is approved for marketing in Japan.

Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.

Inavir® is registered to Daiichi Sankyo.



CONTACT:

Biota Holdings Limited
Investor / Analyst Enquiries
Peter Cook, T: +61 3 9915 3720
or
Damian Lismore, T: +61 3 9915 3721
or
Hinton & Associates
Media Enquiries
Nerida Mossop, T: +61 3 9600 1979 / M: +61 437 361 433
or
Blueprint Life Science Group
US Enquiries
Hershel Berry, M: +1-415-505-3749

KEYWORDS:   Australia  United States  North America  Australia/Oceania  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Pharmaceutical  General Health

MEDIA:

Suggested Articles

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.